Symtuza
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Darunavir;cobicistat;emtricitabine;tenofovir alafenamide
- Made by
- Janssen-Cilag International
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). Genotypic testing should guide the use of Symtuza.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Janssen-Cilag International |
|---|---|
| Active substance | Darunavir;cobicistat;emtricitabine;tenofovir alafenamide |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR22 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2017-09-21 |
| Last updated by the regulator | 2026-09-16 |
| EMA product number | EMEA/H/C/004391 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).